<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of hemodialysis arteriovenous fistula maintenance and thrombosis prevention</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of hemodialysis arteriovenous fistula maintenance and thrombosis prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of hemodialysis arteriovenous fistula maintenance and thrombosis prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Allon, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ellen D Dillavou, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2443631037"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This topic provides an overview of general issues regarding arteriovenous (AV) fistula maintenance, including measures to prevent AV fistula thrombosis and management of the high-risk fistula. These same considerations with respect to AV grafts are reviewed separately. (See  <a class="medical medical_review" href="/d/html/1950.html" rel="external">"Overview of hemodialysis arteriovenous graft maintenance and thrombosis prevention"</a>.)</p><p class="headingAnchor" id="H1321460741"><span class="h1">RISK FACTORS FOR AV FISTULA THROMBOSIS</span><span class="headingEndMark"> — </span>Many factors influence the choice of type and location for AV fistula creation and should be taken into account during patient selection and surgical creation of the fistula [<a href="#rid1">1</a>]. Although some of these factors affect outcomes, once the access has been placed, they cannot generally be modified. </p><p>Other factors that can lead to AV fistula dysfunction and thrombosis include:</p><p class="bulletIndent1"><span class="glyph">●</span>Preexisting stenotic lesions</p><p class="bulletIndent1"><span class="glyph">●</span>Cannulation injury/more frequent cannulation (ie, daily hemodialysis)</p><p class="bulletIndent1"><span class="glyph">●</span>Infiltration/hematoma formation</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombosis of a pseudoaneurysm [<a href="#rid2">2</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent stenosis</p><p class="bulletIndent1"><span class="glyph">●</span>Prior stenting</p><p></p><p class="headingAnchor" id="H726729688"><span class="h1">ROUTINE FISTULA MAINTENANCE AND CARE</span><span class="headingEndMark"> — </span>Proper fistula maintenance and care can help prevent injury to the fistula that might lead to problems. Proper cannulation technique is paramount for preventing injury to the fistula that might cause infiltration/hematoma formation that might lead to thrombosis or intimal injury that might lead to future stenosis.</p><p class="headingAnchor" id="H1872182307"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>All AV fistulas should be evaluated after their creation for appropriate fistula maturation and, once matured, examined at each dialysis session and monitored for any problems with dialysis. (See  <a class="medical medical_review" href="/d/html/1924.html" rel="external">"Physical examination of the mature hemodialysis arteriovenous fistula"</a> and  <a class="medical medical_review" href="/d/html/1970.html" rel="external">"Clinical monitoring and surveillance of the mature hemodialysis arteriovenous fistula"</a>.)</p><p>Patients should be taught to examine the AV fistula between dialysis sessions for a thrill. If a thrill cannot be felt or there is a change from the prior examination or there is redness or swelling of the arm, the patient should inform the staff at the dialysis unit [<a href="#rid3">3,4</a>]. Patients with a functioning fistula who are not yet on dialysis therapy should also be taught to examine the access.</p><p class="headingAnchor" id="H1110087009"><span class="h2">Cannulation and decannulation</span><span class="headingEndMark"> — </span>Proper cannulation and decannulation are important for preventing complications that can reduce the survival of the AV fistula. Hemodialysis staff should be appropriately trained, and only those with technical mastery should be allowed to cannulate a newly created fistula [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H2422681642"><span class="h3">Inspection prior to initial cannulation</span><span class="headingEndMark"> — </span>The newly created AV fistula should be examined by an experienced clinician no later than four to six weeks after creation to determine if the AV fistula is clinically usable [<a href="#rid5">5</a>]. The AV fistula must be physiologically mature with an appropriate depth, length, and location that allows cannulation with a minimal risk for infiltration and the ability to deliver adequate blood flow [<a href="#rid6">6</a>]. The physical examination measures of maturation are reviewed separately. (See  <a class="medical medical_review" href="/d/html/97013.html" rel="external">"Early evaluation of the newly created hemodialysis arteriovenous fistula"</a>.)</p><p>If the AV fistula is judged to be ready, cannulation and hemodialysis can be initiated. (See <a class="local">'General procedure'</a> below.)</p><p class="headingAnchor" id="H3042767581"><span class="h3">Standard versus buttonhole technique</span><span class="headingEndMark"> — </span>The standard technique for repeatedly cannulating an AV fistula is using the "rope-ladder" technique. Another technique is the buttonhole technique, also referred to as the constant-site technique. For patients undergoing standard dialysis at outpatient centers (three times weekly), we suggest the standard technique. The buttonhole technique may improve fistula survival but may be associated with more pain and an increased risk for bloodstream infection. </p><p>The rope-ladder technique simply involves rotating the cannulation sites between hemodialysis sessions, whereas the buttonhole technique deliberately cannulates the same site each time [<a href="#rid7">7-10</a>]. It takes up to 10 cannulations (more for patients with diabetes) to develop an epithelialized track that allows the use of a dull bevel (antistick) needle [<a href="#rid9">9</a>]. Once this occurs, standard sharp needles are avoided, though the ideal approach is still under study [<a href="#rid11">11,12</a>]. More pressure and more needle manipulation are needed to cannulate the AV fistula using antistick needles, which can lead to bleeding from the needle site during hemodialysis.</p><p>Although it had been suggested that the buttonhole technique may improve fistula survival, it may be associated with an increased risk for bloodstream infections [<a href="#rid13">13-21</a>]. Thus, it is not generally used among patients undergoing standard dialysis at outpatient centers. The more common practice in such units is to cannulate the AV fistula at different sites or rotating sites each dialysis session. An exception would be a short AV fistula that has insufficient length to permit rotation of cannulation site [<a href="#rid13">13,22,23</a>]. (See <a class="local">'General procedure'</a> below.) </p><p>Systematic reviews have compared standard with buttonhole cannulation [<a href="#rid13">13,14</a>]. Although observational trials have suggested a difference between the techniques for perceived pain with cannulation, among the randomized trials, there was no difference. Studies evaluating infection have reported a trend toward an increase in infectious events for those using buttonhole cannulation. The results of the two largest trials are briefly summarized.</p><p class="bulletIndent1"><span class="glyph">●</span>One trial compared AV fistula survival among 127 patients randomly assigned to standard or buttonhole technique at three outpatient dialysis sites [<a href="#rid15">15</a>]. At one year, AV fistula survival was lower for patients using the standard compared with buttonhole technique (86 versus 100 percent). Fewer patients using the standard technique were free from any intervention to maintain patency (49 versus 74 percent). However, 14 patients assigned to the buttonhole technique switched to the standard technique (eight patients who had pain associated with the technique, four in whom the buttonhole could not be established, and two who transferred out of the study center).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another trial of 140 hemodialysis patients randomized to either the standard or buttonhole technique, the rate of localized infection was higher for the buttonhole group (50 versus 22.4 per 1000) at eight weeks [<a href="#rid19">19</a>]. At 12 months, the number of needling-site abscesses requiring intravenous antibiotics was also higher in the buttonhole group (nine versus none). In a later follow-up of this trial, buttonhole cannulation was not associated with improved AV fistula survival [<a href="#rid20">20</a>].</p><p></p><p>The use of the buttonhole technique among patients who undergo short daily hemodialysis or nocturnal hemodialysis is discussed separately. (See  <a class="medical medical_review" href="/d/html/1898.html" rel="external">"Short daily hemodialysis", section on 'Vascular access'</a> and  <a class="medical medical_review" href="/d/html/1904.html" rel="external">"Technical aspects of nocturnal hemodialysis", section on 'Fistulas and grafts'</a>.)</p><p class="headingAnchor" id="H1961457256"><span class="h3">General procedure</span><span class="headingEndMark"> — </span>Regardless of which cannulation method is used, appropriate technique should be used. We recommend wearing gloves and masks during cannulation and appropriate hand cleansing and antiseptic cleansing of the cannulation site [<a href="#rid24">24</a>]. Full barrier precautions (gowns, drapes) are generally not needed. Dialysis unit personnel should wear a gown if there is risk of contamination of field (eg, uncontrolled diarrhea or wound drainage not contained by a dressing) [<a href="#rid25">25</a>].</p><p>These minimal standards reduce the transmission but are variably used in observational studies that have compared different dialysis facilities [<a href="#rid26">26</a>]. Preventing disease transmission is important, particularly given the increasing microbial resistance to mainstream antibiotics [<a href="#rid25">25</a>].</p><p>We generally cannulate a new AV fistula with a 17 gauge needle and limit dialysis blood flow to 200 mL/min, although there are no good studies that have shown a benefit to this approach. If successful, at subsequent dialysis sessions, the needle gauge can progressively be increased to 16 g and then 15 g, and the dialysis blood flow progressively increased from 200 to 450 mL/min. In general, a dialysis blood flow of 300 mL/min requires a 16 g needle, and a blood flow of 400 mL/min requires a 15 g needle. Each dialysis unit should have an established protocol for increasing the needle size and blood flow when initiating cannulation of new AV fistulas.</p><p class="headingAnchor" id="H2899932738"><span class="h3">Cannulating a fistula</span><span class="headingEndMark"> — </span>Our approach for cannulating an AV fistula is as follows [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Locate, inspect, and palpate the needle cannulation sites prior to skin preparation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Wash the access site using an antibacterial soap or scrub and water.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cleanse the skin using 2% <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a> gluconate/70% isopropyl alcohol. Although less preferred, alternatives are 10% <a class="drug drug_general" data-topicid="9801" href="/d/drug information/9801.html" rel="external">povidone iodine</a> and/or 70% alcohol.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the skin is touched by the patient or staff after the skin prep has been applied but the cannulation has not been completed, repeat the preparation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Once the preparation is completed, apply tourniquet above the puncture site to increase venous pressure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The use of a wet needle is safer and also prevents the risk for a blood spray or spill, especially for the initial AV fistula cannulation. Attach a 10 mL syringe filled with 8 mL of normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> solution to prime the AV fistula needle immediately before use, then clamp the needle.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Apply traction to the skin in an opposite direction to the direction of needle insertion, avoiding excessive pressure that can flatten the vein.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Insert the needle bevel up at an approximately 15 degree angle. Arterial needle direction can be antegrade or retrograde to direction of blood flow; venous needle should be antegrade to direction of blood flow.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Once the vein has been penetrated, blood flashback will be visible (the needle may need to be unclamped to see the blood flashback); flatten the angle of the advance of the needle slowly. Remove the tourniquet, and tape the needle onto the skin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Confirm needle placement with a normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> flush before connecting the needles to the blood pump and starting the pump. Blood return alone is not enough to show good needle placement. After flashback is visible, aspirate 1 to 5 mL with the 10 mL syringe, then flush the needle with the normal saline solution, looking for any signs of infiltration, then clamp the needle.</p><p></p><p class="headingAnchor" id="H1451901394"><span class="h3">Decannulating a fistula</span><span class="headingEndMark"> — </span>Proper needle removal prevents postdialysis infiltrations. Our approach to decannulating a fistula is as follows [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Remove the needle at approximately the same angle used for insertion. Using too steep an angle during needle removal may cause the tip to puncture the back wall.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Apply the gauze dressing over the needle site, but do not apply pressure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Apply pressure only after the needle has been completely removed. Take care to properly clot the needle tract and not the fistula.</p><p></p><p class="headingAnchor" id="H1353607554"><span class="h3">Cannulation difficulty or failure</span><span class="headingEndMark"> — </span>As noted, veins that are difficult to see and feel should be identified with a duplex ultrasound and marked with an indelible marker prior to dialysis. (See <a class="local">'Inspection prior to initial cannulation'</a> above.)</p><p>If cannulation is unsuccessful, recannulation should not be attempted again until the site has healed.</p><p>Infiltration associated with cannulation sites can occur at any time during dialysis. The patient should be monitored closely during the dialysis procedure for signs and symptoms of infiltration (pain, bruising, oozing). If infiltration occurs, application of ice can help decrease the pain and size of the infiltration and may decrease bleeding time [<a href="#rid3">3</a>]. A quick response to a needle infiltration can help minimize damage to the access.</p><p class="bulletIndent1"><span class="glyph">●</span>Avoid lifting up on the needle after it is in the vein, and use care when taping needles in place. Improper needle placement or taping procedure can cause infiltration, as can improper decannulation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For infiltration occurring during the initial cannulation, release the tourniquet immediately.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the fistula has infiltrated, it is best to rest the fistula for at least one treatment, but, if this is not possible, the next cannulation should be above the site of the infiltration. If the patient still has a catheter in place, restart use of the fistula with one needle.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For infiltration that occurs after the administration of heparin, leaving the needle in place and cannulating at another site may be appropriate.</p><p></p><p class="headingAnchor" id="H2687861440"><span class="h2">Care between dialysis sessions</span><span class="headingEndMark"> — </span>In between dialysis sessions, patients are instructed to keep the fistula clean and avoid wearing any clothing, jewelry, or other activities that restrict flow to or from the access. Bathing and other activities can be resumed as normally tolerated.</p><p class="headingAnchor" id="H2086413375"><span class="h1">HIGH-RISK AV FISTULAS</span><span class="headingEndMark"> — </span>(See <a class="local">'Risk factors for AV fistula thrombosis'</a> above.)</p><p class="headingAnchor" id="H3694391011"><span class="h2">Nonmaturing AV fistula</span><span class="headingEndMark"> — </span>For patients who have a newly created AV fistula that has not matured, an imaging study should be obtained.<strong> </strong>A postoperative ultrasound is frequently used first to determine the cause. The most common abnormality is a juxta-anastomotic stenosis (within 2 cm of the anastomosis), which can be treated with balloon angioplasty. Occasionally, ligation of collateral veins can help mature the fistula by redirecting all the arterial blood into a single venous channel. (See  <a class="medical medical_review" href="/d/html/96402.html" rel="external">"Primary failure of the hemodialysis arteriovenous fistula"</a> and  <a class="medical medical_review" href="/d/html/1910.html" rel="external">"Endovascular intervention for the treatment of stenosis in the arteriovenous access"</a>.)</p><p>There are no proven pharmacologic therapies for improving AV fistula maturation, although some are under investigation and may prove useful. (See <a class="local">'Ineffective and investigational therapies'</a> below.)</p><p class="headingAnchor" id="H1901320140"><span class="h2">Venous stenotic lesions</span><span class="headingEndMark"> — </span>As with the developing AV fistula, stenotic lesions responsible for the failure of a matured AV fistula are predominantly related to a juxta-anastomotic lesion. Many therapies have been used in an attempt to reduce AV fistula thrombosis, including antiplatelet agents and fish oil [<a href="#rid27">27</a>]. None of these have proven effective for improving AV fistula survival or other clinically meaningful outcomes. (See <a class="local">'Ineffective and investigational therapies'</a> below.)</p><p>Treatment of stenotic lesions is balloon angioplasty; however, the need for angioplasty to correct a venous stenotic lesion is, in itself, a risk factor for future AV fistula failure. The AV fistula with recurrent stenosis has even higher failure rates. (See  <a class="medical medical_review" href="/d/html/1957.html" rel="external">"Failure of the mature hemodialysis arteriovenous fistula"</a> and  <a class="medical medical_review" href="/d/html/1910.html" rel="external">"Endovascular intervention for the treatment of stenosis in the arteriovenous access"</a>.)</p><p class="headingAnchor" id="H72171421"><span class="h2">Thrombosis without identified stenotic lesion</span><span class="headingEndMark"> — </span>On rare occasions, AV fistula thrombosis can occur in the absence of an identified stenotic lesion. The cause is unclear. A hypercoagulable condition is rarely the cause of AV fistula thrombosis [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H2880199064"><span class="h2">AV fistula with aneurysm</span><span class="headingEndMark"> — </span>Excessive dilation of the vein under pressure can thin the vessel wall and lead to focal aneurysm formation. Aneurysms uncommonly cause AV fistula failure unless they are very large. By contrast, pseudoaneurysms, which may result from repeated cannulation at one site (not to be confused with the constant-site or buttonhole technique), may rupture or become infected. The clinical features and management of aneurysms and pseudoaneurysms associated with AV hemodialysis are reviewed separately. (See  <a class="medical medical_review" href="/d/html/14023.html" rel="external">"Arteriovenous graft creation for hemodialysis and its complications"</a> and  <a class="medical medical_review" href="/d/html/1917.html" rel="external">"Arteriovenous fistula creation for hemodialysis and its complications", section on 'Aneurysm/pseudoaneurysm/megafistula'</a>.)</p><p class="headingAnchor" id="H3213601894"><span class="h2">Secondary AV fistula</span><span class="headingEndMark"> — </span>Among patients with a prior failed AV fistula, a secondary fistula is often possible (<a class="graphic graphic_algorithm graphicRef101882" href="/d/graphic/101882.html" rel="external">algorithm 1</a>). The risk factors for AV fistula failure are likely similar to those for failure of the initial access; however, the fact that the first access has failed may compound the risk. (See  <a class="medical medical_review" href="/d/html/1835.html" rel="external">"Hemodialysis access following a failed arteriovenous access"</a>.)</p><p>Failure of maturation and stenotic lesions associated with secondary AV fistulas are treated in an analogous manner as with the initial fistula. (See <a class="local">'Nonmaturing AV fistula'</a> above and <a class="local">'Venous stenotic lesions'</a> above.)</p><p>No pharmacologic therapies are known to increase the likelihood of secondary fistula success or improve long-term secondary AV fistula survival. Although these patients are at risk for AV fistula failure, assisted patency rates are similar to those of the initial access; however, as noted in the linked topic, these results reflect a selected group. (See  <a class="medical medical_review" href="/d/html/1835.html" rel="external">"Hemodialysis access following a failed arteriovenous access", section on 'SAVF series results'</a>.)</p><p class="headingAnchor" id="H1369024091"><span class="h1">INEFFECTIVE AND INVESTIGATIONAL THERAPIES</span><span class="headingEndMark"> — </span>Most pharmacologic therapies studied are aimed at preventing neointimal hyperplasia. None have proven useful for preventing thrombosis of AV fistulas.</p><p>Similarly, there are no proven pharmacologic therapies for improving AV fistula maturation, and none can be recommended. However, emerging evidence suggests that inadequate outward remodeling (ie, suboptimal sustained dilation of the AV fistula) is an important factor in nonmaturation. Some degree of neointimal hyperplasia is observed in almost all AV fistulas, and many AV fistulas mature in spite of the presence of a stenosis, provided there is adequate outward remodeling. Some research suggests that chronic kidney disease may reduce nitric oxide (NO) signaling [<a href="#rid29">29</a>]. Whether targeting NO resistance with novel agents will prove beneficial remains to be seen.</p><p class="headingAnchor" id="H906878102"><span class="h2">Antithrombotic therapies</span><span class="headingEndMark"> — </span>In randomized trials, systemic anticoagulation at the time of AV fistula creation is associated with increased bleeding complications with no benefit in terms of AV fistula patency [<a href="#rid30">30,31</a>]. </p><p>Many antiplatelet agents have also been used in an attempt to reduce AV fistula thrombosis, but none have been shown to reliably reduce the rate of AV fistula failure [<a href="#rid27">27</a>]. Among the many available agents, predominantly those that block cyclo-oxygenase (<a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, sulfinpyrazone) and the platelet P2Y12 receptor blockers (<a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>, <a class="drug drug_general" data-topicid="9996" href="/d/drug information/9996.html" rel="external">ticlopidine</a>) have been studied for reducing AV fistula thrombosis. Other antiplatelet therapies, including the protease-activated receptor-1 antagonists (<a class="drug drug_general" data-topicid="95242" href="/d/drug information/95242.html" rel="external">vorapaxar</a>) and the glycoprotein IIb/IIIa receptor blockers, have not been evaluated for this clinical indication.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> therapy does not appear to improve AV fistula patency rates. A large multicenter trial randomly assigned 407 of 567 patients (concurrent fish oil trial) with newly created AV fistulas to receive aspirin (100 mg/day) or placebo starting one day prior to AV fistula creation and continued for 12 weeks [<a href="#rid32">32</a>]. At 12 months follow-up, the risk of fistula failure was similar between the aspirin and placebo arms (45 versus 43 percent; relative risk [RR] 1.05, 95% CI 0.84-1.31) [<a href="#rid32">32</a>]. In an earlier trial, 92 patients were assigned to placebo or aspirin (Colfarit) starting the day before AV fistula creation and continued to 28 days afterwards [<a href="#rid33">33</a>]. In this study, aspirin did reduce the rate of AV fistula thrombosis (2 of 45 versus 11 of 47; 4.4 versus 23.4 percent). However, more patients in the placebo group had diminished arterial flow (six versus one), which may reflect use of inadequate vessels. The criteria for creation of an AV fistula have since been standardized, and the relevance of this trial in contemporary practice is questionable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two small trials have compared <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> with placebo in newly created AV fistulas [<a href="#rid34">34,35</a>]. In the larger of the two (n = 877), the rate of early thrombosis was reduced for patients who received clopidogrel (300 mg load, followed by 75 mg daily), but there was no difference in the proportion of fistulas that became suitable for dialysis (&gt;300 mL/minute during 8 of 12 dialysis sessions) [<a href="#rid34">34</a>]. In the other, a smaller trial of 93 patients, the rate of primary fistula failure trended lower for clopidogrel (5.2 versus 21.6 percent; hazard ratio 0.72, 95% CI 0.41-1.01). The attempt at first hemodialysis using the newly created AV fistula was more successful in the clopidogrel compared with placebo group (92.3 versus 70.5 percent), though success rates through multiple sessions were not reported [<a href="#rid35">35</a>]. Clopidogrel was discontinued prematurely in 19.4 percent of patients primarily due to side effects (11 of 18 who discontinued).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The results of small studies using <a class="drug drug_general" data-topicid="9996" href="/d/drug information/9996.html" rel="external">ticlopidine</a> have been mixed [<a href="#rid36">36-38</a>]. In a multicenter, randomized trial of 250 patients, ticlopidine did not significantly reduce AV fistula thrombosis compared with placebo (12 versus 19 percent; odds ratio [OR] 0.60, 95% CI 0.30-1.18) [<a href="#rid36">36</a>]. In another small trial of 42 patients, AV fistula thrombosis occurred in fewer patients who received ticlopidine compared with placebo (11 versus 47 percent, OR 0.13, 95% CI 0.02-0.76) [<a href="#rid37">37</a>].</p><p></p><p class="headingAnchor" id="H1440021719"><span class="h2">Fish oil</span><span class="headingEndMark"> — </span>A benefit for fish oil (omega-3-acid-ethyl esters) with respect to access survival as seen with AV grafts has not been demonstrated for AV fistulas, and we suggest not administering fish oil for the sole purpose of preventing thrombosis. Nevertheless, the administration of fish oil may be indicated for other clinically relevant cardiovascular benefits (eg, blood pressure lowering, reducing adverse cardiovascular events), particularly among individuals with coronary heart disease and its risk equivalents [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/7190.html" rel="external">"Chronic kidney disease and coronary heart disease"</a> and  <a class="medical medical_review" href="/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p><p>Omega-3-acid-ethyl esters inhibit cyclo-oxygenase (thereby prolonging bleeding times) and may reduce intimal hyperplasia, which is an important cause of hemodialysis AV access failure. While the majority of trials evaluating the effectiveness of fish oil for reducing AV access failure have been performed in the setting of AV grafts, one large multicenter trial randomly assigned 567 patients with newly created AV fistulas to receive fish oil (4 g/day) or placebo for 12 weeks [<a href="#rid32">32</a>]. At 12 months follow-up, no differences between the groups were observed for the primary composite outcome of AV fistula failure (47 percent in each group) or for any of the individual outcomes (fistula thrombosis, fistula abandonment, cannulation failure).</p><p class="headingAnchor" id="H3476095314"><span class="h2">Phosphodiesterase inhibitors</span><span class="headingEndMark"> — </span>The phosphodiesterase inhibitor, <a class="drug drug_general" data-topicid="8872" href="/d/drug information/8872.html" rel="external">cilostazol</a>, has been studied for maturation of fistulas. In a small nonrandomized study, 33 patients received cilostazol for ≥30 days prior to creation of a dialysis access, continuing cilostazol therapy for ≥60 days after surgery [<a href="#rid40">40</a>]. The matched control group included 116 patients who underwent the same procedure but did not receive cilostazol before or after surgery. The cilostazol group was more likely to experience fistula maturation compared with controls (88 versus 66 percent; RR 3.8, 95% CI 1.3-11.6). Additional controlled studies are need to confirm this effect.</p><p class="headingAnchor" id="H666138623"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112932.html" rel="external">"Society guideline links: Dialysis"</a> and  <a class="medical medical_society_guidelines" href="/d/html/132674.html" rel="external">"Society guideline links: Hemodialysis vascular access"</a>.)</p><p class="headingAnchor" id="H2290241609"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Many factors predispose to primary failure or failure of the mature arteriovenous (AV) fistula. Proper routine AV fistula care and maintenance can help prevent injury to the fistula that can lead to dysfunction and thrombosis. (See <a class="local">'Risk factors for AV fistula thrombosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The newly created AV fistula should be examined by an experienced clinician no later than four to six weeks after creation to determine if the AV fistula is clinically usable. If the AV fistula is judged to be ready, cannulation and hemodialysis can be initiated. If successful, the needle gauge and blood flow rate can be progressively increased at subsequent sessions. (See <a class="local">'Inspection prior to initial cannulation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Proper cannulation and decannulation are important for preventing complications, and only those with technical proficiency should be allowed to cannulate an AV fistula. (See <a class="local">'Cannulation and decannulation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition to routine monitoring in the dialysis unit, patients should be taught to examine their AV fistula routinely, and, if a thrill cannot be felt or if there is redness or swelling of the arm, the patient should inform the staff at the dialysis unit. Patients are instructed to keep the fistula clean and to avoid wearing any clothing, jewelry, or other activities that restrict flow to or from the access. (See <a class="local">'Monitoring'</a> above and <a class="local">'Care between dialysis sessions'</a> above and  <a class="medical medical_review" href="/d/html/97013.html" rel="external">"Early evaluation of the newly created hemodialysis arteriovenous fistula"</a> and  <a class="medical medical_review" href="/d/html/1970.html" rel="external">"Clinical monitoring and surveillance of the mature hemodialysis arteriovenous fistula"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two techniques are used for repeatedly cannulating the AV fistula: the standard, "rope-ladder" technique and the "buttonhole," or constant-site, technique. The rope-ladder technique uses a different cannulation site for each dialysis session, whereas the buttonhole technique deliberately cannulates the same site each time. For patients undergoing standard dialysis at outpatient centers, we suggest the standard technique (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). The buttonhole technique may improve fistula survival, but it appears to be associated with more pain and an increased risk for bloodstream infection. (See <a class="local">'Standard versus buttonhole technique'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Regardless of which cannulation method is used, sterile precautions should be used including appropriate hand cleansing, antiseptic cleansing of the cannulation site, and the use of gloves and masks during cannulation. Full barrier precautions (gowns, drapes) are generally not needed. (See <a class="local">'General procedure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The technique for properly cannulating and decannulating an AV fistula and techniques to manage common problems are described above. (See <a class="local">'General procedure'</a> above and <a class="local">'Cannulation difficulty or failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have an AV fistula that has not matured, has matured but is dysfunctional, or has thrombosed, further evaluation should be undertaken to identify any stenotic lesions (juxta-anastomotic stenosis is most common), which can be treated with balloon angioplasty. (See <a class="local">'Nonmaturing AV fistula'</a> above and <a class="local">'Venous stenotic lesions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although there is some support for use of pharmacologic therapies for the prevention of thrombosis in AV grafts, data for any benefit with AV fistulas are lacking. Thus, for patients with newly created AV fistulas, we suggest not using <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>), other antiplatelet agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>), or fish oil (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>) for the sole purpose of preventing thrombosis. Further, we recommend not using systemic anticoagulation given the increased risk of bleeding without demonstrated benefit (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Nevertheless, the administration of antiplatelet therapies and fish oil are associated with clinically relevant cardiovascular benefits (eg, blood pressure lowering, adverse cardiovascular events) and may be indicated, particularly among individuals with coronary heart disease and its risk equivalents. (See <a class="local">'Ineffective and investigational therapies'</a> above and  <a class="medical medical_review" href="/d/html/7190.html" rel="external">"Chronic kidney disease and coronary heart disease"</a> and  <a class="medical medical_review" href="/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lok CE, Huber TS, Lee T, et al. KDOQI Vascular Access Guidelines Work Group. KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis 2020; 75:S1.</a></li><li><a class="nounderline abstract_t">Mudoni A, Cornacchiari M, Gallieni M, et al. Aneurysms and pseudoaneurysms in dialysis access. Clin Kidney J 2015; 8:363.</a></li><li class="breakAll">https://www.kidney.org/sites/default/files/docs/12-50-0210_jag_dcp_guidelines-va_oct06_sectionc_ofc.pdf (Accessed on March 13, 2017).</li><li class="breakAll">https://www.pennmedicine.org/departments-and-centers/department-of-radiology/patient-care/radiology/interventional-radiology/procedures-and-services/hemodialysis-access (Accessed on March 13, 2017).</li><li><a class="nounderline abstract_t">Saran R, Dykstra DM, Pisoni RL, et al. Timing of first cannulation and vascular access failure in haemodialysis: an analysis of practice patterns at dialysis facilities in the DOPPS. Nephrol Dial Transplant 2004; 19:2334.</a></li><li><a class="nounderline abstract_t">Beathard GA. An algorithm for the physical examination of early fistula failure. Semin Dial 2005; 18:331.</a></li><li class="breakAll">Twardowski ZJ, Harper G. Buttonhole method of needle insertion into arteriovenous fistulas. 1997.</li><li><a class="nounderline abstract_t">Twardowski Z, Kubara H. Different sites versus constant sites of needle insertion into arteriovenous fistulas for treatment by repeated dialysis. Dial Transpl 1979; 8:978.</a></li><li><a class="nounderline abstract_t">Hashmi A, Cheema MQ, Moss AH. Hemodialysis patients' experience with and attitudes toward the buttonhole technique for arteriovenous fistula cannulation. Clin Nephrol 2010; 74:346.</a></li><li><a class="nounderline abstract_t">Nesrallah GE, Cuerden M, Wong JH, Pierratos A. Staphylococcus aureus bacteremia and buttonhole cannulation: long-term safety and efficacy of mupirocin prophylaxis. Clin J Am Soc Nephrol 2010; 5:1047.</a></li><li><a class="nounderline abstract_t">Morselli C, Chiari P, Aliberti T, et al. SHARP VERSUS BLUNT DIALYSIS NEEDLE USE WITH BUTTONHOLE METHOD: OPEN RANDOMISED TRIAL. J Ren Care 2015; 41:213.</a></li><li><a class="nounderline abstract_t">Jennings WC, Galt SW, Shenoy S, et al. The Venous Window Needle Guide, a hemodialysis cannulation device for salvage of uncannulatable arteriovenous fistulas. J Vasc Surg 2014; 60:1024.</a></li><li><a class="nounderline abstract_t">Wong B, Muneer M, Wiebe N, et al. Buttonhole versus rope-ladder cannulation of arteriovenous fistulas for hemodialysis: a systematic review. Am J Kidney Dis 2014; 64:918.</a></li><li><a class="nounderline abstract_t">Wang LP, Tsai LH, Huang HY, et al. Effect of buttonhole cannulation versus rope-ladder cannulation in hemodialysis patients with vascular access: A systematic review and meta-analysis of randomized/clinical controlled trials. Medicine (Baltimore) 2022; 101:e29597.</a></li><li><a class="nounderline abstract_t">Vaux E, King J, Lloyd S, et al. Effect of buttonhole cannulation with a polycarbonate PEG on in-center hemodialysis fistula outcomes: a randomized controlled trial. Am J Kidney Dis 2013; 62:81.</a></li><li><a class="nounderline abstract_t">Struthers J, Allan A, Peel RK, Lambie SH. Buttonhole needling of ateriovenous fistulae: a randomized controlled trial. ASAIO J 2010; 56:319.</a></li><li><a class="nounderline abstract_t">Chow J, Rayment G, San Miguel S, Gilbert M. A randomised controlled trial of buttonhole cannulation for the prevention of fistula access complications. J Ren Care 2011; 37:85.</a></li><li><a class="nounderline abstract_t">Toma S, Shinzato T, Fukui H, et al. A timesaving method to create a fixed puncture route for the buttonhole technique. Nephrol Dial Transplant 2003; 18:2118.</a></li><li><a class="nounderline abstract_t">MacRae JM, Ahmed SB, Atkar R, Hemmelgarn BR. A randomized trial comparing buttonhole with rope ladder needling in conventional hemodialysis patients. Clin J Am Soc Nephrol 2012; 7:1632.</a></li><li><a class="nounderline abstract_t">Macrae JM, Ahmed SB, Hemmelgarn BR, Alberta Kidney Disease Network. Arteriovenous fistula survival and needling technique: long-term results from a randomized buttonhole trial. Am J Kidney Dis 2014; 63:636.</a></li><li><a class="nounderline abstract_t">Lyman M, Nguyen DB, Shugart A, et al. Risk of Vascular Access Infection Associated With Buttonhole Cannulation of Fistulas: Data From the National Healthcare Safety Network. Am J Kidney Dis 2020; 76:82.</a></li><li><a class="nounderline abstract_t">Di Nicolò P, Cornacchiari M, Mereghetti M, Mudoni A. Buttonhole Cannulation of the AV Fistula: A Critical Analysis of the Technique. Semin Dial 2017; 30:32.</a></li><li><a class="nounderline abstract_t">Atkar RK, MacRae JM. The buttonhole technique for fistula cannulation: pros and cons. Curr Opin Nephrol Hypertens 2013; 22:629.</a></li><li><a class="nounderline abstract_t">Tokars JI, Arduino MJ, Alter MJ. Infection control in hemodialysis units. Infect Dis Clin North Am 2001; 15:797.</a></li><li class="breakAll">https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5005a1.htm (Accessed on March 13, 2017).</li><li><a class="nounderline abstract_t">Arenas MD, Sánchez-Payá J, Barril G, et al. A multicentric survey of the practice of hand hygiene in haemodialysis units: factors affecting compliance. Nephrol Dial Transplant 2005; 20:1164.</a></li><li><a class="nounderline abstract_t">Mohamed I, Kamarizan MFA, Da Silva A. Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database Syst Rev 2021; 7:CD002786.</a></li><li><a class="nounderline abstract_t">Eleftheriadis T, Antoniadi G, Akritidou A, et al. A case report of recurrent vascular access thrombosis in a hemodialysis patient reveals combined acquired and inherited thrombophilia. Ther Apher Dial 2008; 12:190.</a></li><li><a class="nounderline abstract_t">Geenen IL, Kolk FF, Molin DG, et al. Nitric Oxide Resistance Reduces Arteriovenous Fistula Maturation in Chronic Kidney Disease in Rats. PLoS One 2016; 11:e0146212.</a></li><li><a class="nounderline abstract_t">Bhomi KK, Shrestha S, Bhattachan CL. Role of systemic anticoagulation in patients undergoing vascular access surgery. Nepal Med Coll J 2008; 10:222.</a></li><li><a class="nounderline abstract_t">D'Ayala M, Smith RM, Martone C, et al. The effect of systemic anticoagulation in patients undergoing angioaccess surgery. Ann Vasc Surg 2008; 22:11.</a></li><li><a class="nounderline abstract_t">Irish AB, Viecelli AK, Hawley CM, et al. Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis: A Randomized Clinical Trial. JAMA Intern Med 2017; 177:184.</a></li><li><a class="nounderline abstract_t">Andrassy K, Malluche H, Bornefeld H, et al. Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid. Results of a prospective double blind study. Klin Wochenschr 1974; 52:348.</a></li><li><a class="nounderline abstract_t">Dember LM, Beck GJ, Allon M, et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA 2008; 299:2164.</a></li><li><a class="nounderline abstract_t">Ghorbani A, Aalamshah M, Shahbazian H, et al. Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients. Indian J Nephrol 2009; 19:57.</a></li><li><a class="nounderline abstract_t">Gröntoft KC, Larsson R, Mulec H, et al. Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scand J Urol Nephrol 1998; 32:276.</a></li><li><a class="nounderline abstract_t">Gröntoft KC, Mulec H, Gutierrez A, Olander R. Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scand J Urol Nephrol 1985; 19:55.</a></li><li><a class="nounderline abstract_t">Fiskerstrand CE, Thompson IW, Burnet ME, et al. Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. Artif Organs 1985; 9:61.</a></li><li><a class="nounderline abstract_t">Dixon BS. Fish oil and hemodialysis graft patency: does time matter? JAMA 2012; 307:1859.</a></li><li><a class="nounderline abstract_t">Russell TE, Kasper GC, Seiwert AJ, et al. Cilostazol May Improve Maturation Rates and Durability of Vascular Access for Hemodialysis. Vasc Endovascular Surg 2017; 51:120.</a></li></ol></div><div id="topicVersionRevision">Topic 112108 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : KDOQI Vascular Access Guidelines Work Group. KDOQI clinical practice guideline for vascular access: 2019 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26251700" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Aneurysms and pseudoaneurysms in dialysis access.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26251700" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Aneurysms and pseudoaneurysms in dialysis access.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26251700" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Aneurysms and pseudoaneurysms in dialysis access.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15252160" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Timing of first cannulation and vascular access failure in haemodialysis: an analysis of practice patterns at dialysis facilities in the DOPPS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16076357" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : An algorithm for the physical examination of early fistula failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16076357" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : An algorithm for the physical examination of early fistula failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Different sites versus constant sites of needle insertion into arteriovenous fistulas for treatment by repeated dialysis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20979942" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hemodialysis patients' experience with and attitudes toward the buttonhole technique for arteriovenous fistula cannulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20413438" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Staphylococcus aureus bacteremia and buttonhole cannulation: long-term safety and efficacy of mupirocin prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25819209" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : SHARP VERSUS BLUNT DIALYSIS NEEDLE USE WITH BUTTONHOLE METHOD: OPEN RANDOMISED TRIAL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24833247" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The Venous Window Needle Guide, a hemodialysis cannulation device for salvage of uncannulatable arteriovenous fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25110302" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Buttonhole versus rope-ladder cannulation of arteriovenous fistulas for hemodialysis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35866782" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effect of buttonhole cannulation versus rope-ladder cannulation in hemodialysis patients with vascular access: A systematic review and meta-analysis of randomized/clinical controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23473984" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effect of buttonhole cannulation with a polycarbonate PEG on in-center hemodialysis fistula outcomes: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20418768" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Buttonhole needling of ateriovenous fistulae: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21561544" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A randomised controlled trial of buttonhole cannulation for the prevention of fistula access complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13679489" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A timesaving method to create a fixed puncture route for the buttonhole technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22822010" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A randomized trial comparing buttonhole with rope ladder needling in conventional hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24239019" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Arteriovenous fistula survival and needling technique: long-term results from a randomized buttonhole trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32151430" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Risk of Vascular Access Infection Associated With Buttonhole Cannulation of Fistulas: Data From the National Healthcare Safety Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27678339" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Buttonhole Cannulation of the AV Fistula: A Critical Analysis of the Technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24076555" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The buttonhole technique for fistula cannulation: pros and cons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11570142" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Infection control in hemodialysis units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11570142" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Infection control in hemodialysis units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15769816" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A multicentric survey of the practice of hand hygiene in haemodialysis units: factors affecting compliance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34298589" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18387172" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A case report of recurrent vascular access thrombosis in a hemodialysis patient reveals combined acquired and inherited thrombophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26727368" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Nitric Oxide Resistance Reduces Arteriovenous Fistula Maturation in Chronic Kidney Disease in Rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19558057" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Role of systemic anticoagulation in patients undergoing vascular access surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18055171" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The effect of systemic anticoagulation in patients undergoing angioaccess surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28055065" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4600820" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid. Results of a prospective double blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18477783" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20368925" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9764456" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3895411" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3888153" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22550201" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Fish oil and hemodialysis graft patency: does time matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28183219" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cilostazol May Improve Maturation Rates and Durability of Vascular Access for Hemodialysis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
